Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer By Ogkologos - April 16, 2026 33 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase III study in patients recruited through the PATCH and STAMPEDE-1 trial networks Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Dabrafenib and Trametinib Incorporating sTILs Into PREDICT Substantially Improves the Model’s Ability to Distinguish High- and Low-Risk Patients with TNBC Your NCI: Top Priorities from AACR 2026 MOST POPULAR New on NCI’s Websites for November 2021 November 5, 2021 FDA Grants Accelerated Approval to Ponatinib with Chemotherapy for Newly Diagnosed... March 29, 2024 Junk food marketing restrictions: so near and yet so far December 15, 2022 Relugolix Approval Expected to Alter Treatment for Advanced Prostate Cancer January 26, 2021 Load more HOT NEWS Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress Patient Guide in Testicular Cancer Now Available Also in Italian Mother Of 6 With ‘Open-Door Policy’ Packs 100 Lunches For Hungry... A Subset of Patients with NSCLC Respond Poorly to the COVID-19...
